Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Recently released market study: Corneal Neovascularization - Pipeline Review, H2 2013


Print article Print article
2014-01-27 08:55:12 - Fast Market Research recommends "Corneal Neovascularization - Pipeline Review, H2 2013" from Global Markets Direct, now available

Global Markets Direct's, 'Corneal Neovascularization - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Corneal Neovascularization, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Corneal Neovascularization. Corneal Neovascularization - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
- www.fastmr.com/prod/769210_corneal_neovascularization_pipeline_r ..

Note*: Certain sections in the report may be removed or altered based on the availability

and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Corneal Neovascularization.
* A review of the Corneal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Corneal Neovascularization pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Corneal Neovascularization.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Corneal Neovascularization pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: F. Hoffmann-La Roche Ltd., GTx, Inc., Circadian Technologies Limited, Sirnaomics, Inc., Amakem NV

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Corneal Neovascularization Overview
Therapeutics Development
Pipeline Products for Corneal Neovascularization - Overview
Pipeline Products for Corneal Neovascularization - Comparative Analysis
Corneal Neovascularization - Therapeutics under Development by Companies
Corneal Neovascularization - Therapeutics under Investigation by Universities/Institutes
Corneal Neovascularization - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Corneal Neovascularization - Products under Development by Companies
Corneal Neovascularization - Products under Investigation by Universities/Institutes
Corneal Neovascularization - Companies Involved in Therapeutics Development
F. Hoffmann-La Roche Ltd.
GTx, Inc.
Circadian Technologies Limited
Sirnaomics, Inc.
Amakem NV
Corneal Neovascularization - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Assessment by Therapeutic Class
Drug Profiles
ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VGX-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pSEC.siRNA.VEGFA Loaded Poly Lactic Co-Glycolic Acid Nanoparticles - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STP-601 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Beta-LGND2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Raver-2 Protein for Corneal Neovascularization and Vision - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMA-0526 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Corneal Neovascularization - Recent Pipeline Updates
Corneal Neovascularization - Dormant Projects
Corneal Neovascularization - Product Development Milestones
Featured News & Press Releases
Jul 01, 2010: Results of a Meta-Analysis Show Neovascularization Increases Risk For Corneal Transplant Rejection And Failure
Sep 01, 2009: Gene Signal GS-101 Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth
Aug 11, 2009: Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 For Diseases Of The Eye
Sep 18, 2003: QLT Announces the Completion of Development Milestones in its Continued Efforts to Expand the Availability of Visudyne in Wet AMD Market
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Corneal Neovascularization, H2 2013
Number of Products under Development for Corneal Neovascularization - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Clinical Stage Development, H2 2013
Comparative Analysis by Early Stage Development, H2 2013

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=769210&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser